Cayston

Osteomyelitis, Gonorrhea, Septicemia + 11 more
Treatment
7 FDA approvals
20 Active Studies for Cayston

What is Cayston

AztreonamThe Generic name of this drug
Treatment SummaryCefoperazone is an antibiotic used to treat infections caused by certain types of bacteria. It is especially effective against gram-negative bacteria, which are usually found in the bladder, kidneys, and meninges. Cefoperazone is resistant to beta-lactamases, which are enzymes produced by some bacteria to protect themselves from antibiotics, making it more effective than other antibiotics. However, it may cause a secondary infection with gram-positive bacteria.
Azactamis the brand name
image of different drug pills on a surface
Cayston Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Azactam
Aztreonam
2009
15

Approved as Treatment by the FDA

Aztreonam, commonly known as Azactam, is approved by the FDA for 7 uses which include Urinary Tract Infection and Communicable Diseases .
Urinary Tract Infection
Communicable Diseases
Skin Infections
Intraabdominal Infections
Gram-Negative Bacterial Infections
Septicemia
Lower Respiratory Tract Infection (LRTI)

Effectiveness

How Cayston Affects PatientsAztreonam is a type of antibiotic that is effective against many types of gram-negative aerobic bacteria, including Pseudomonas aeruginosa. It has no effect on gram-positive bacteria or anaerobes. This antibiotic has been nicknamed the "magic bullet for aerobic gram-negative bacteria" because it is so effective. Aztreonam is resistant to beta-lactamases (enzymes produced by many types of bacteria) and maintains its effectiveness even in the presence of human serum and in anaerobic conditions. It also works over a wide range of pH levels, from 6 to 8.
How Cayston works in the bodyAztreonam works by stopping bacteria from forming a protective cell wall. It binds to a protein called PBP3 and stops it from creating the wall. Without this wall, the bacteria is unable to survive and is destroyed by its own enzymes. Aztreonam may also interfere with an enzyme that keeps these autolytic enzymes from destroying the cell.

When to interrupt dosage

The suggested dosage of Cayston is contingent upon the identified condition, such as Intraabdominal Infections, Gram-Negative Bacterial Infections and Lower Respiratory Tract Infection (LRTI). The amount of dosage is contingent upon the method of delivery (e.g. Injection, powder, lyophilized, for solution - Intramuscular; Intravenous or Powder, for suspension - Respiratory (inhalation)) featured in the following table.
Condition
Dosage
Administration
Osteomyelitis
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Septic Arthritis
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Intraabdominal Infections
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Urinary Tract Infection
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Gonorrhea
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Pseudomonas Aeruginosa Infection
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Bone and Joint Infections
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Lower Respiratory Tract Infection (LRTI)
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Cystic Fibrosis (CF)
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Skin Infections
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Gram-Negative Bacterial Infections
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Communicable Diseases
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Septicemia
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Febrile Neutropenia
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution

Warnings

There are 20 known major drug interactions with Cayston.
Common Cayston Drug Interactions
Drug Name
Risk Level
Description
Vibrio cholerae CVD 103-HgR strain live antigen
Major
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Aztreonam.
Abacavir
Minor
Aztreonam may decrease the excretion rate of Abacavir which could result in a higher serum level.
Aclidinium
Minor
Aztreonam may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Minor
Aztreonam may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Aztreonam may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.

Cayston Novel Uses: Which Conditions Have a Clinical Trial Featuring Cayston?

33 active clinical trials are currently being conducted to examine the potential of Cayston to alleviate Bone and Joint Infections, Cystic Fibrosis (CF) and Gram-Negative Bacterial Infections.
Condition
Clinical Trials
Trial Phases
Bone and Joint Infections
0 Actively Recruiting
Septicemia
1 Actively Recruiting
Not Applicable
Gonorrhea
0 Actively Recruiting
Septic Arthritis
1 Actively Recruiting
Not Applicable
Gram-Negative Bacterial Infections
4 Actively Recruiting
Phase 2, Phase 3
Lower Respiratory Tract Infection (LRTI)
1 Actively Recruiting
Phase 3
Urinary Tract Infection
8 Actively Recruiting
Not Applicable, Phase 4, Phase 3
Febrile Neutropenia
2 Actively Recruiting
Phase 2, Phase 4
Communicable Diseases
0 Actively Recruiting
Pseudomonas Aeruginosa Infection
0 Actively Recruiting
Osteomyelitis
6 Actively Recruiting
Phase 4, Phase 2, Phase 3, Not Applicable
Cystic Fibrosis (CF)
0 Actively Recruiting
Intraabdominal Infections
4 Actively Recruiting
Not Applicable, Phase 4
Skin Infections
2 Actively Recruiting
Phase 2, Not Applicable

Cayston Reviews: What are patients saying about Cayston?

5Patient Review
1/24/2020
Cayston for Respiratory Cystic Fibrosis with Pseudomonas aeruginosa Colonization
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about cayston

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What kind of drug is CAYSTON?

"CAYSTON is a prescription antibacterial medicine that is used to improve breathing symptoms in people with cystic fibrosis who have a lung infection due to Pseudomonas aeruginosa. CAYSTON is not for infections caused by other bacteria or viruses, such as the common cold."

Answered by AI

What is CAYSTON used to treat?

"This mucus is also found in the pancreas and in the intestine.

This medication is used to treat people who have cystic fibrosis and a persistent lung infection with Pseudomonas aeruginosa. people with cystic fibrosis produce thick, sticky mucus that can plug up the tubes, ducts and passageways in the lungs. This mucus is also found in the pancreas and in the intestine."

Answered by AI

How long does CAYSTON last?

"You can store CAYSTON at room temperature for up to 28 days, as long as it's in a cool, dark place."

Answered by AI

How do you administer CAYSTON?

"To administer CAYSTON, pour the reconstituted solution into the handset of the nebulizer system. To start, turn the unit on. While holding the handset's mouthpiece in your mouth, breathe normally only through your mouth. The entire administration process usually takes between 2 and 3 minutes."

Answered by AI

Clinical Trials for Cayston

Have you considered Cayston clinical trials? We made a collection of clinical trials featuring Cayston, we think they might fit your search criteria.
Have you considered Cayston clinical trials? We made a collection of clinical trials featuring Cayston, we think they might fit your search criteria.
Have you considered Cayston clinical trials? We made a collection of clinical trials featuring Cayston, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top